Kikuchi H, Shigeno C, Lee K, Ohta S, Shiomi K, Ikeda T, Sone T, Dokoh S, Konishi J
Department of Radiology and Nuclear Medicine, University Hospital, Sakyo, Japan.
Endocrinology. 1991 Mar;128(3):1229-37. doi: 10.1210/endo-128-3-1229.
Purified native forms of human parathyroid hormone-related peptide (PTHrp) have recently been reported to display biological activities characteristic of transforming growth factor beta (TGF-beta). The TGF-beta-like property of PTHrp may reside within the amino N-terminal PTH-receptor binding region of the polypeptide, since a synthetic analog corresponding to amino acids 1-36 of human PTHrp is as active as purified native PTHrp in bioassays specific to TGF-beta. Complete lack of structural similarity between PTHrp and TGF-beta prompted us to address the question whether copresence of the TGF-beta-like and PTH-like biological activities in the N-terminal sequence of the PTHrp molecule is a general phenomenon observable with different N-terminal PTHrp peptides of varying amino acid chain length in a variety of target cells that respond in defined ways to TGF-beta in vitro. Two forms of synthetic N-terminal human PTHrp, PTHrp-(1-34) and [Tyr40]PTHrp-(1-40), which are fully active in conventional assays for PTH/PTHrp, were tested for effects in three in vitro bioassay systems for TGF-beta: 1) stimulation, and 2) inhibition, respectively, of epidermal growth factor-dependent soft-agar colony formation of either normal rat kidney-derived fibroblasts (NRK 49F) or human lung carcinoma cells (A549); and 3) biosynthesis of metabolically labeled fibronectin in both NRK 49F cells and clonal osteoblastic rat osteosarcoma cells (ROS 17/2.8). Human TGF-beta over the dose range of 2.5-80 pM significantly stimulated or inhibited soft-agar colony formation of either NRK 49F or A549 cells, respectively, and caused a severalfold increase in biosynthetically labeled [35S]fibronectin in NRK 49F and ROS 17/2.8 cells. In contrast, none of PTHrp-(1-34), [Tyr40]PTHrp-(1-40), and synthetic human PTH-(1-34), each tested at 0.1-10 nM, displayed detectable biological activity in any of the three assay systems. In addition, covalent cross-linking of intact NRK 49F and ROS 17/2.8 cells with either [125I]TGF-beta or 125I-[Tyr40] PTHrp-(1-40) revealed the presence of several distinct affinity-labeled receptor species for TGF-beta in both cell types and the 80K PTH/PTHrp receptors in ROS 17/2.8 cells. The affinity-labeled TGF-beta receptor species were insensitive to excess PTHrp and PTH peptides, and the 80K PTH/PTHrp receptors were insensitive to excess TGF-beta, indicating that PTHrp and TGF-beta do not cross-react with respect to receptor binding for interaction with these cells.(ABSTRACT TRUNCATED AT 400 WORDS)
最近有报道称,纯化的天然形式的人甲状旁腺激素相关肽(PTHrp)具有转化生长因子β(TGF-β)的生物学活性特征。PTHrp的TGF-β样特性可能存在于该多肽的氨基N末端PTH受体结合区域内,因为在针对TGF-β的生物测定中,与人PTHrp的氨基酸1-36相对应的合成类似物与纯化的天然PTHrp具有相同的活性。PTHrp与TGF-β之间完全缺乏结构相似性,这促使我们探讨PTHrp分子N末端序列中TGF-β样和PTH样生物学活性的共存是否是一种普遍现象,在多种以特定方式对体外TGF-β作出反应的靶细胞中,不同氨基酸链长度的N末端PTHrp肽是否都能观察到这种现象。两种合成的N末端人PTHrp,即PTHrp-(1-34)和[Tyr40]PTHrp-(1-40),它们在传统的PTH/PTHrp测定中具有完全活性,在三种TGF-β的体外生物测定系统中测试其作用:1)分别刺激和2)抑制正常大鼠肾脏来源的成纤维细胞(NRK 49F)或人肺癌细胞(A549)的表皮生长因子依赖性软琼脂集落形成;3)在NRK 49F细胞和克隆性成骨样大鼠骨肉瘤细胞(ROS 17/2.8)中代谢标记纤连蛋白的生物合成。在2.5-80 pM的剂量范围内,人TGF-β分别显著刺激或抑制NRK 49F或A549细胞的软琼脂集落形成,并使NRK 49F和ROS 17/2.8细胞中生物合成标记的[35S]纤连蛋白增加数倍。相比之下,PTHrp-(1-34)、[Tyr40]PTHrp-(1-40)和合成人PTH-(1-34)在0.1-10 nM的浓度下进行测试时,在任何一种测定系统中均未显示出可检测到的生物学活性。此外,完整的NRK 49F和ROS 17/2.8细胞与[125I]TGF-β或125I-[Tyr40]PTHrp-(1-40)的共价交联显示,两种细胞类型中均存在几种不同的TGF-β亲和标记受体物种,以及ROS 17/2.8细胞中的80K PTH/PTHrp受体。亲和标记的TGF-β受体物种对过量的PTHrp和PTH肽不敏感,80K PTH/PTHrp受体对过量的TGF-β不敏感,这表明PTHrp和TGF-β在与这些细胞相互作用的受体结合方面不会发生交叉反应。(摘要截短至400字)